section name header

Pronunciation

kris-a-BOR-ole

Classifications

Therapeutic Classification: anti-inflammatories

Pharmacologic Classification: phosphodiesterase type 4 inhibitors

Indications

REMS


Action

  • Inhibits phosphodiesterase 4 (PDE-4) resulting in intracellular cyclic adenosine monophosphate levels.
Therapeutic effects:
  • Decreased severity of atopic dermatitis.

Pharmacokinetics

Absorption: Minimal systemic absorption through intact skin.

Distribution: Local distribution after topical administration.

Protein Binding: 97%.

Metabolism/Excretion: Metabolized through liver into inactive metabolites; metabolites excreted in urine.

Half-Life: Unknown.

Time/Action Profile

(improvement in symptoms)

ROUTEONSETPEAKDURATION
Topical8 daysunknownunknown



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: burning, stinging

Misc: hypersensitivity reactions

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Eucrisa